Overview

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

For unresectable locally-advanced non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial. However, it is unclear whether surgery can provide survival benefit for patients with tumors initially unresectable transformed into resectable ones after chemoimmunotherapy. This trial aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Pulmonary Hospital, Shanghai, China

Treatments:

Carboplatin
Paclitaxel
Pemetrexed